From Awareness to Action: Transforming Proton Pump Inhibitor Use in Ras Al Khaimah Through Education and Intervention: the RAK -PRIDE Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 479
- Locations
- 1
- Primary Endpoint
- Proportion of patients who stopped or reduced the dose of PPIs
Study Overview
Brief Summary
The goal of this study is to determine if a pharmacist-led educational intervention can reduce the inappropriate use of proton pump inhibitors (PPIs) among adult patients (≥18 years) with potentially inappropriate PPI prescriptions in Ras Al Khaimah.
The main questions it aims to answer are:
- Can a pharmacist-led education program reduce unnecessary PPI use?
- Does the intervention improve patients' quality of life and reduce healthcare costs? Researchers will compare the intervention group (receiving pharmacist-led education and materials) to the usual care group to see if the intervention reduces PPI use and improves patient outcomes.
Participants will:
- Receive educational materials from pharmacists, including a patient educational brochure, PPI patient decision aid, PPI deprescribing pamphlet, and PPI patient action plan.
- Physicians involved will also receive a pharmaceutical intervention, which includes a physician educational brochure, PPI evidence-based deprescribing guideline, PPI deprescribing algorithm, and whiteboard videos on PPI deprescribing.
- Patients will be followed up for 6 months to monitor changes in PPI use, symptoms, and quality of life.
Detailed Description
The RAK-PRIDE Study aims to evaluate the impact of a pharmacist-led educational intervention on the inappropriate use of proton pump inhibitors (PPIs) among adult patients in Ras Al Khaimah. This intervention will focus on both patient education and physician guidance, promoting evidence-based deprescribing practices for PPIs.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Health Services Research
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Physicians will be eligible to participate if:
- •They are prescribing PPIs in outpatient department of the study sites
- •They have patients with potentially inappropriate PPI prescriptions
- •Patients will be eligible to participate if:
- •They are ≥18 years
- •They are presenting to out-patient departments of the study sites
- •They have prescriptions of potentially inappropriate PPIs
- •Their treating physicians are included in the study
Exclusion Criteria
- •Physicians will be excluded if:
- •They are involved in any other prescribing trial
- •Patients will be excluded if:
- •They are unable to give informed consent, as judged by their physicians
- •They have definitive indications for PPI use
Arms & Interventions
Pharmacist-Led Educational Intervention
Physicians and patients in this arm will receive a multi-faceted pharmacist-led educational intervention. This includes evidence-based deprescribing guidelines, brochures, videos, and decision aids to promote appropriate use of PPIs and reduce unnecessary prescriptions. The intervention is delivered in four parts: educational brochures, deprescribing algorithm, patient action plans, and video-based education sessions.
Intervention: Pharmacist-Led Educational Intervention (Other)
Control
Participants in this arm will continue with their usual care without any pharmacist-led intervention during the 6-month study period. Physicians and patients will follow the standard clinical practice for PPI prescriptions.
Intervention: Control (Standard treatment) (Other)
Outcomes
Primary Outcomes
Proportion of patients who stopped or reduced the dose of PPIs
Time Frame: From enrollment to the end of treatment at 6 months
Secondary Outcomes
- Change in PPI dose (cummulative)(From enrollment to the end of treatment at 6 months)
- GERD symptom recurrence using the Gastroesophageal Reflux Disease Impact Scale (GIS) questionnaire(From enrollment to the end of treatment at 6 months)
- Number of Medications(From enrollment to the end of treatment at 6 months)
- Quality of life by EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire(From enrollment to the end of treatment at 6 months)
- Potential adverse effects of PPI use(From enrollment to the end of treatment at 6 months)
- Number of Participants with Prescription of PPIs (Restart or Dose Increase) and/or Alternative Antireflux Treatments(From enrollment to the end of treatment at 6 months)
- Revised Patients' Attitudes Toward Deprescribing (rPATD) questionnaire(From enrollment to the end of treatment at 6 months)
- Health Care Professionals' Attitudes Towards Deprescribing (HATD) Tool(From enrollment to the end of treatment at 6 months)
- Healthcare Costs (Direct Medical Costs of PPI Use)(From enrollment to the end of treatment at 6 months)
- Quality-Adjusted Life Years (QALY) Gains(From enrollment to the end of treatment at 6 months)
- Cost per QALY Gained (Incremental Cost-Effectiveness Ratio, ICER)(From enrollment to the end of treatment at 6 months)
Investigators
Syed Arman Rabbani
Professor Syed Arman Rabbani
RAK Medical and Health Sciences University